Vectura Group has collaborated with Propeller Health to develop digitally-connected inhalers to address chronic respiratory diseases.

The companies will use Vectura’s dry powder inhaler (DPI) technology and Propeller’s FDA-cleared digital health platform to develop the new inhalers.

Initially, the firms will focus on the development of an add-on sensor for Vectura’s lever-operated multi-dose inhaler (LOMI).

The LOMI device is said to leverage key attributes from Vectura’s GyroHaler device, including user interface and drug delivery components.

Vectura CEO James Ward-Lilley said: "This announcement demonstrates Vectura’s commitment to develop next generation inhalation devices that can help patients manage their respiratory diseases better.

"Adherence to therapy is one of the major issues driving poor maintenance management of these chronic conditions."

Propeller Health CEO David Van Sickle said: "Digital health has the potential to make respiratory therapies more personal, powerful and convenient for every patient."

Vectura provides a range of pre-metered foil blister-based dry powder inhalers, while Propeller offers digital health platform for asthma and chronic obstructive pulmonary disease (COPD).